%PDF-1.4
%
33 0 obj
<>
endobj
30 0 obj
<>
endobj
86 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-26T13:03:34Z
2024-03-29T08:51:16-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T08:51:16-07:00
application/pdf
Heather
201334.suppl.62
uuid:5653781e-1dd2-11b2-0a00-7f0927bd7700
uuid:56537822-1dd2-11b2-0a00-900000000000
endstream
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
104 0 obj
[108 0 R]
endobj
105 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2001, V)110.8 (olume 28, Supplement 62)]TJ
0 Tw -37.5268 -0.0313 Td
(20)Tj
ET
0 0 0 0 scn
/GS0 gs
101.02 59.75 407.5 -10.83 re
f*
0.5 w
101.02 59.75 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.02499 Tw 7.76 0 0 8 57.3 714.5293 Tm
[(18.)-644.3 (W)79.8 (eaver )54.9 (A, Chatwell R, Churchill M, et al. Improved gastrointestinal)]TJ
1.8943 -1.25 Td
(tolerance and patient preference of enteric-coated sulfasalazine versus)Tj
0 -1.25 TD
(uncoated sulfasalazine tablets in patients with rheumatoid arthritis. )Tj
T*
(J Clin Rheumatol 1999;5:193-200.)Tj
-1.8943 -1.25 Td
[(19.)-644.3 (El Maghraoui )54.8 (A, Borderie D, Cherruau B, Edouard R, Dougados M,)]TJ
1.8943 -1.25 Td
(Roux C. Osteoporosis, body composition, and bone turnover in)Tj
T*
(ankylosing spondylitis. J Rheumatol 1999;26:2205-9.)Tj
-1.8943 -1.25 Td
[(20.)-644.3 (Pennanen N, Lapinjoki S, Urtti )54.8 (A, Monkkonen J. Ef)17.8 (fect of liposomal)]TJ
1.8943 -1.25 Td
[(and free bisphosphonates on the IL-1\337, IL-6 and )17.8 (TNF-)]TJ
/T1_0 1 Tf
0 Tw 21.9791 0 Td
(\002)Tj
/TT1 1 Tf
-0.00011 Tc 0.9059 0 Td
(secretion)Tj
0 Tc 0.0249 Tw -22.8849 -1.25 Td
[(from RA)79.8 (W)-257.2 (264 cells )]TJ
/TT0 1 Tf
8.6108 0 Td
[(in vitr)36.9 (o)]TJ
/TT1 1 Tf
2.9044 0 Td
(. Pharm Res 1995;12:916-22.)Tj
-0.00011 Tc -13.4095 -1.25 Td
[(21.)-644.4 (Maksymowych )17.7 (WP)110.7 (, Jhangri GS, Leclercq S, Skeith K, )36.8 (Y)100 (a)-0.1 ( )54.8 (A, Russell)]TJ
0 Tc 1.8943 -1.25 Td
[(AS. )54.9 (An open study of pamidronate in the treatment of refractory)]TJ
T*
(ankylosing spondylitis. J Rheumatol 1998;25:714-7.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(22.)-644.4 (Moreira )54.8 (AL, Sampaio EP)110.7 (, Zmuidzinas )54.8 (A, Frindt P)110.7 (, Smith KA, Kaplan)]TJ
0 Tc 1.8943 -1.25 Td
[(G. )17.8 (Thalidomide exerts its inhibitory action on tumor necrosis factor)]TJ
T*
[(alpha by enhancing mRNA)-220.1 (degradation. J Exp Med 1993;)]TJ
0 Tw T*
(177:1675-80.)Tj
0.0249 Tw -1.8943 -1.25 Td
[(23.)-644.3 (Moller DR, )17.7 (W)59.8 (ysocka M, Greenlee BM, et al. Inhibition of IL-12)]TJ
1.8943 -1.25 Td
(production by thalidomide. J Immunol 1997;159:5157-61.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(24.)-644.4 (Breban M, Gombert B, )54.8 (Amor B, Dougados M. Ef)17.7 (ficacy of)]TJ
0 Tc 1.8943 -1.25 Td
(thalidomide in the treatment of refractory ankylosing spondylitis.)Tj
T*
(Arthritis Rheum 1999;42:580-1.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(25.)-644.4 (El Hassani S, Dougados M, Gombert B, )54.8 (Amor B, Breban M.)]TJ
1.8943 -1.25 Td
[(T)34.8 (reatment of severe refractory spondyloarthropathy \(SP)91.7 (A\) with)]TJ
0 Tc T*
[(thalidomide: results of an open study [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1999;42:S373.)Tj
-0.00011 Tc 0.02499 Tw -1.8943 -1.25 Td
[(26.)-644.4 (W)79.7 (einblatt ME, Kremer JM, Bankhurst )54.8 (AD, et al. )54.8 (A)-219.9 (trial of etanercept,)]TJ
0 Tc 1.8943 -1.25 Td
(a recombinant tumor necrosis factor receptor: FC fusion protein, in)Tj
T*
(patients with rheumatoid arthritis receiving methotrexate. N Engl J)Tj
T*
(Med 1999;28:253-9.)Tj
-1.8943 -1.25 Td
[(27.)-644.3 (Mielants H, )17.7 (V)111.1 (eys EM. Inflammation of the ileum in patients with)]TJ
1.8943 -1.25 Td
(B27-positive reactive arthritis. Lancet 1984;1:288.)Tj
-1.8943 -1.25 Td
[(28.)-644.3 (Dougados M, )54.8 (Alemanni M, )17.7 (T)34.9 (ulliez M, et al. Ileocolonoscopie)]TJ
1.8943 -1.25 Td
(systematique au cours des sponndyloarthropathies seronegatives. Rev)Tj
T*
(Rheum Mal Osteoartic 1987;54:279-83.)Tj
-0.00011 Tc 32.1263 42.5 Td
[(29.)-644.4 (van den Bosch F)79.7 (, Kruithof E, Baeten D, de Keyser F)79.7 (, Mielants H,)]TJ
1.8943 -1.25 Td
[(V)111 (eys EM. Ef)17.7 (fects of a loading dose regimen of three infusions of)]TJ
0 Tc T*
(chimeric monoclonal antibody to tumour necrosis factor )Tj
/T1_0 1 Tf
0 Tw 22.917 0 Td
(\002)Tj
/TT1 1 Tf
0.02499 Tw -22.917 -1.25 Td
[(\(infliximab\) in spondyloarthropathy: an open pilot study)64.9 (. )54.9 (Ann Rheum)]TJ
T*
(Dis 2000;59:428-33.)Tj
-1.8943 -1.25 Td
[(30.)-644.3 (Brandt J, Haibel H, Cornely D, et al. Successful treatment of active)]TJ
1.8943 -1.25 Td
[(ankylosing spondylitis with the anti-tumor necrosis factor)19.8 (-)]TJ
/T1_0 1 Tf
0 Tw 23.5678 0 Td
(\002)Tj
/TT1 1 Tf
0.02499 Tw -23.5678 -1.25 Td
[(monoclonal antibody infliximab. )54.9 (Arthritis Rheum 2000;43:1346-52.)]TJ
-0.00011 Tc -1.8943 -1.25 Td
[(31.)-644.4 (Braun J, Sieper J. )54.8 (Anti-TNF-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 13.5469 0 Td
(\002)Tj
/TT1 1 Tf
0.02499 Tw [0.1 (: a new dimension in the)]TJ
-11.6525 -1.25 Td
[(pharmacotherapy of the spondyloarthropathies!? )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(2000;59:404-6.)Tj
-0.00011 Tc 0.02499 Tw -1.8943 -1.25 Td
[(32.)-644.4 (Ferraz MB, )17.7 (T)34.8 (ugwell P)110.7 (, Goldsmith CH, )54.8 (Atra E. Meta analysis of)]TJ
0 Tc 1.8943 -1.25 Td
(sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.)Tj
-1.8943 -1.25 Td
[(33.)-644.3 (T)69.8 (aggart )54.8 (AJ, Gardiner PV)128.9 (, McEvoy FM, et al. )17.7 (Which is the active)]TJ
1.8943 -1.25 Td
[(moiety of sulfasalazine in ankylosing spondylitis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1996;39:1400-5.)Tj
0.02499 Tw -1.8943 -1.25 Td
[(34.)-644.3 (Chapman CM, Zwillich SH. Olsalazine in ankylosing spondylitis: a)]TJ
1.8943 -1.25 Td
[(pilot study)64.9 (. J Rheumatol 1994;21:1699-701.)]TJ
-1.8943 -1.25 Td
[(35.)-644.3 (Y)100.1 (amane K, Saito C, Natsuda H, et al. )54.9 (Ankylosing spondylitis)]TJ
1.8943 -1.25 Td
(successfully treated with methotrexate. Intern Med 1993;32:53-6.)Tj
-1.8943 -1.25 Td
[(36.)-644.3 (Handler RP)110.8 (. Favorable results using methotrexate in treatment of)]TJ
1.8943 -1.25 Td
[(patients with ankylosing spondylitis. )54.9 (Arthritis Rheum 1989;32:234.)]TJ
-1.8943 -1.25 Td
[(37.)-644.3 (Bardin )17.8 (T)74 (, Enel C, Cornelis F)79.8 (, et al. )54.9 (Antibiotic treatment of venereal)]TJ
1.8943 -1.25 Td
[(disease and Reiter)-36.9 (\222)55.2 (s syndrome in a Greenland population. )54.9 (Arthritis)]TJ
T*
(Rheum 1992;35:190-4.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(38.)-644.4 (T)69.7 (oivanen )54.8 (A, )36.8 (Yli-Kerttula )17.7 (T)73.9 (, Luukkainen R, Merilahti-Palo R, Granfors)]TJ
0 Tc 1.8943 -1.25 Td
[(K, Seppala J. Ef)17.8 (fect of antimicrobial treatment on chronic reactive)]TJ
T*
[(arthritis. Clin Exp Rheumatol 1993;1)36.9 (1:301-7.)]TJ
-0.00011 Tc -1.8943 -1.25 Td
[(39.)-644.4 (Dougados M, Berenbaum F)79.7 (,)-0.1 ( Maetzel )54.8 (A, )54.8 (Amor B. )17.7 (The use of)]TJ
0 Tc 1.8943 -1.25 Td
(sulfasalazine for the prevention of attacks of acute anterior uveitis)Tj
T*
[(associated with spondylarthropathy)64.9 (. Rev Rhum \(Engl Ed\) 1993;)]TJ
0 Tw T*
(60:80-2.)Tj
ET
0 0 0 0 scn
468 770 90 -25 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
20.37 0 0 21 469 753.6089 Tm
(201334-5)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
13 0 obj
<>
endobj
75 0 obj
<>
endobj
91 0 obj
<>
endobj
36 0 obj
<>
endobj
39 0 obj
<>
endobj
51 0 obj
<>
endobj
53 0 obj
<>
endobj
69 0 obj
<>stream
HVT{g@ (:XVTGacwt>kFOccTEDVkL4 -'6*VHI{3ܹYf{
?ڳux4űa CtlC-%1bҴKI.nhSteD}lhX3WY6{^{3Xç(㻇6?Id>x}ZKYo3bƬٌbfyŪ;oz+VBUX7Xn'+UW >؛+ wR
0cLJGB*X6%2
qX
#
ͻ"yJyg%36:>C
R7.kN,q%:^V
Z{F#g&Fa=.KtAB&Yn\4@F*kc Ca)^&k%aVcއ3I^z^⒜#7+GԶf4Tƾ|L^@G| b.11og5ܣT1MŢHyLŇ!ɓm+ι#ten8QE7DT,u1.QTd-؏ߛ#Q&TCBr\-ayQP+dUuz^,zMkbwQ:˸[Ҩ)ESwJɂdWjwp<9[w݊J)3 u3Ts<0/a>r=un>Q|Y/7>:"x:7i&?M -m!:Btxsx_I9IR"&
M&hg-;wuNݶ`Mn O]p~d~xW]4FRCE7{"VvvR
V+Np{ c:'pܻ&n?zC~gb \ˢRMzTSgSvSƑ._Hb3YymT\PnëwBJbHiƊ;tOL=f@sL5VmD}udD[""o^DY;=f; 9s88ޤRc #lTaYvbXN>\Q eFȔ~}D$3p9L1EfjgUέt`pipS$d˃LaOUW